Lecanemab made headlines as the first MHRA-approved drug in the UK to slow early-stage Alzheimer’s disease, but it has not been recommended for use on the NHS. Here is what we know so far about this breakthrough Alzheimer's drug.
Lecanemab made headlines as the first MHRA-approved drug in the UK to slow early-stage Alzheimer’s disease, but it has not been recommended for use on the NHS. Here is what we know so far about this breakthrough Alzheimer's drug.
Getting an early and accurate dementia diagnosis will only become more important as new treatments become available, so research into this area is vital.
Getting an early and accurate dementia diagnosis will only become more important as new treatments become available, so research into this area is vital.
Research studies offer hope that we can one day end the devastation caused by dementia – and research is only possible thanks to the people who take part.